Meptid 100mg/1ml solution for injection ampoules

Country: United Kingdom

Bahasa: Inggeris

Sumber: MHRA (Medicines & Healthcare Products Regulatory Agency)

Bahan aktif:

Meptazinol hydrochloride

Boleh didapati daripada:

Almirall Ltd

Kod ATC:

N02AX05

INN (Nama Antarabangsa):

Meptazinol hydrochloride

Dos:

100mg/1ml

Borang farmaseutikal:

Solution for injection

Laluan pentadbiran:

Intramuscular; Intravenous

Kelas:

No Controlled Drug Status

Jenis preskripsi:

Valid as a prescribable product

Ringkasan produk:

BNF: 04070200; GTIN: 5021840006606

Risalah maklumat

1
PACKAGE LEAFLET: INFORMATION FOR THE USER
MEPTID 100 MG/ML SOLUTION FOR INJECTION
Meptazinol
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even if their
symptoms are the same as yours.
-
If any of the side effects gets serious, or if you notice any side
effects not listed in this leaflet, please
tell your doctor or pharmacist.
IN THIS LEAFLET
:
1.
What Meptid Injection is and what it is used for
2.
Before Meptid Injection is used
3.
How Meptid Injection is used
4.
Possible side effects
5.
How to store Meptid Injection
6.
Further information
1.
WHAT MEPTID INJECTION IS AND WHAT IT IS USED FOR
The name of this medicine is Meptid 100 mg/ml Solution for Injection
but will be referred to as Meptid
Injection throughout the remainder of the leaflet.
Meptid Injection belongs to a group of medicines known as opioid
analgesics, which are used to relieve pain.
It contains meptazinol as the active ingredient.
Meptid Injection is used to treat moderate to severe pain, including
post-operative pain, pain during
childbirth and the pain of renal colic.
2.
BEFORE MEPTID INJECTION IS USED
DO NOT USE MEPTID INJECTION IF YOU
-
are allergic (hypersensitive) to Meptazinol or any of the other
ingredients of Meptid Injection
_(see _
_Section 6 ‘Further information’)_
-
have any alcohol-related problems
-
have or you are at risk of getting the condition known as paralytic
ileus
-
have a head injury, or build-up of pressure in the head (raised
intracranial pressure)
-
are having problems breathing
-
are suffering from a tumour of the adrenal gland (phaeochromocytoma)
-
are having an asthma attack
-
are taking medicines known as monoamine-oxidase inhibitors(MAOIs) or
have stopped taking MAOIs
less than 14 days ago
TAKE SPECIAL CARE WITH MEPTID INJECTION IF YOU
-
have any liver or kidney problems
-

Ciri produk

OBJECT 1
MEPTID INJECTIONS
Summary of Product Characteristics Updated 24-Jun-2015 | Almirall
Limited
1. Name of the medicinal product
Meptid 100mg/ml Solution for injection
2. Qualitative and quantitative composition
Each 1 ml of solution contains 100mg of meptazinol (as hydrochloride).
For a full list of excipients, see section 6.1.
3. Pharmaceutical form
Solution for injection.
Clear colourless solution free from particulate matter.
4. Clinical particulars
4.1 Therapeutic indications
For the treatment of moderate to severe pain, including post-operative
pain, obstetric pain and the pain of
renal colic.
4.2 Posology and method of administration
Adults
Intramuscular dosage: 75-100mgMeptid. The injection may be repeated
2-4 hourly as required. For
obstetric pain a dose of 100-150mg should be used according to weight.
This dose should approximate
2mg/kg.
Intravenous dosage: 50-100mg Meptid by slow intravenous injection. The
injection may be repeated 2-4
hourly as required. If vomiting occurs, a suitable antiemetic should
be given.
Epidural/intrathecal use: This formulation is not suitable for these
routes.
Elderly
The adult dosage schedule can be used in the elderly.
Children
Meptid injection has not been evaluated for use in children.
4.3 Contraindications
Patients with the following conditions:
- known hypersensitivity to the active ingredient or to any of the
excipients
- acute alcoholism and where there is a risk of paralytic ileus
- raised intracranial pressure or head injury (in addition to
interfering with respiration, affect pupillary
responses vital for neurological assessment)
- phaeochromocytoma (risk of pressor response to histamine release)
- acute respiratory depression
- during an asthma attack
- patients on monoamine-oxidase inhibitors (MAOIs) and for 14 days
after discontinuing an MAOI. (see
section 4.5)
4.4 Special warnings and precautions for use
Caution should be exercised in patients whose respiratory system is
already compromised.
Patients with moderate to severe renal impairment should be giv